Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Risk of Demyelinating Diseases in the Central Nervous System in Patients With Inflammatory Bowel Disease Treated With Tumor Necrosis Factor Inhibitors.
Sox13 functionally complements the related Sox5 and Sox6 as important developmental modulators in mouse spinal cord oligodendrocytes.
MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.
Tysabri® (natalizumab) data at ECTRIMS reaffirm positive effects of treatment for people with relapsing forms of MS
Biological role of Toll-like receptor-4 in the brain.
Erratum to: 'Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial'.
Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression.
Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Mitochondrial dysfunctions in 7-ketocholesterol-treated 158N oligodendrocytes without or with α-tocopherol: Impacts on the cellular profil of tricarboxylic cycle-associated organic acids, long chain saturated and unsaturated fatty acids, oxysterols, chol
Automated brain volumetrics in multiple sclerosis: a step closer to clinical application.
Promoting peripheral myelin repair.
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris.
Ultrasound of inherited vs. acquired demyelinating polyneuropathies.
Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
Axonal excitability in X-linked dominant Charcot Marie Tooth disease.
Multiple Sclerosis and Fatigue: Understanding the Patient's Needs.
Need for differentiation of real and clinical important change in research on responsiveness of walking outcome measures in multiple sclerosis.
Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.
Smoking and multiple sclerosis susceptibility.
Myoinositol trends in different types of brain lesions.
Cognitive dysfunction in multiple sclerosis: Usually forgotten in the clinical assessment of MS patients.
Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes.
Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab.
Demyelinating disease and psoriasis: Interferon versus dimethyl fumarate.

Pages